You are here

Nanoparticles to Sequester and Facilitate In Vivo Excretion of Lipophilic Molecules

Award Information
Agency: Department of Defense
Branch: Air Force
Contract: FA9550-11-C-0083
Agency Tracking Number: F10B-T24-0132
Amount: $99,993.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: AF10-BT24
Solicitation Number: 2010.B
Solicitation Year: 2010
Award Year: 2011
Award Start Date (Proposal Award Date): 2011-08-01
Award End Date (Contract End Date): N/A
Small Business Information
8100 Shaffer Parkway Suite #130
Littleton, CO -
United States
DUNS: 148034408
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Steve Arzberger
 Program Manager
 (303) 792-5615
Business Contact
 Clifton Brown, Jr.
Title: President&CEO
Phone: (303) 792-5615
Research Institution
 University of Nevada
 Kenneth H Sc.D.
Microbiology&Immunology 199 / School of Medicine
Reno, NV 89557-0046
United States

 (775) 327-5255
 Nonprofit College or University

ABSTRACT: Mycotoxins are lipophilic agents derived from fungus that pose a significant public health problem around the world. The effects of mycotoxins include loss of human and animal life, increased healthcare and veterinary costs, reduced livestock production, and disposal of contaminated foods and feeds. Mycotoxins, such as aflatoxin and T-2 mycotoxins, have been reported to be weaponized as terrorism agents, suggesting the possibility of future deployment against military personnel is a real and present danger. Unfortunately, no effective treatment for mycotoxin exposure in either the acute or chronic setting currently exists. As a result, the United States Air Force has identified the need to fabricate a nanoparticle therapeutic that can sequester and then facilitate the excretion of mycotoxins. To address this need, ADA Technologies Inc. (ADA; Littleton, CO) and Professor Kenneth W. Hunter (University of Nevada at Reno) propose the development of nanoparticles with surface-bound biomolecules for the intravenous binding of lipophilic molecules, sequestration, and excretion from the human body BENEFIT: The proposed program will result in a nanoparticle therapeutic with the demonstrated ability of tightly binding and sequestering lipophilic molecules in solution. The result of the proposed program is anticipated to be the first commercial therapeutic for exposure to fungal toxins. Additional commercial applications may include diagnostics, sensors, and tools for the identification of various harmful molds.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government